Many Americans unaware of increased risk to UV exposure for certain drugs, light-colored eyes

Article

The American Academy of Ophthalmology recently released results of a poll that found the majority of Americans are unaware of the increased risks to ultraviolet (UV) light exposure that are linked to common drugs and having light-colored eyes.

San Francisco-The American Academy of Ophthalmologyrecently released results of a poll that found the majority of Americans are unaware of the increased risks to ultraviolet (UV) light exposure that are linked to common drugs and having light-colored eyes. 

UV exposure can lead to an increased risk of eye cancer, cataracts, photokeratitis, and pterygium. Despite the danger, the poll found nearly half of Americans are unaware that medications can cause photosensitivity-even though about one-third of adults take drugs that increase their susceptibility to UV damage. And while 54 percent of Americans have blue, green, or hazel eyes, only 32 percent of those with light eyes know that they are more susceptible to UV damage.

To make matters worse, the poll found that while 83 percent of Americans wear sunglasses, only about half of those who do wear sunglasses check for a UV protection label before purchasing a pair. And just 32 percent said they make their children wear UV-blocking sunglasses. 

Next: Louisiana to allow ODs to perform certain surgeries

Popular diabetes drug linked to reduced glaucoma risk

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Ramsey discusses innovation for your eye care practice at EyeCon 2024
Dr. Leonard Messner at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
EyeCon 2024: Insights on transforming ocular surface disease management
© 2024 MJH Life Sciences

All rights reserved.